-
Je něco špatně v tomto záznamu ?
Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study
QD. Do, A. Hásková, L. Radovnická, J. Konečná, E. Horová, CG. Parkin, G. Grunberger, M. Prázný, J. Šoupal
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
MH CZ-DRO-VFN64165
Ministry of Health, Czech Republic - conceptual development of research organization, General University Hospital in Prague
Cooperatio Program, research area "Metabolic Diseases", Charles University in Prague
PubMed
37743832
DOI
10.1111/dom.15289
Knihovny.cz E-zdroje
- MeSH
- diabetes mellitus 1. typu * farmakoterapie MeSH
- dospělí MeSH
- glykovaný hemoglobin MeSH
- hypoglykemika terapeutické užití MeSH
- inzulin terapeutické užití MeSH
- inzulinové infuzní systémy MeSH
- inzuliny * MeSH
- krevní glukóza MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- prospektivní studie MeSH
- selfmonitoring glykemie metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- Publikační typ
- časopisecké články MeSH
AIM: To compare open-source AndroidAPS (AAPS) and commercially available Control-IQ (CIQ) automated insulin delivery (AID) systems in a prospective, open-label, single-arm clinical trial. METHODS: Adults with type 1 diabetes who had been using AAPS by their own decision entered the first 3-month AAPS phase then were switched to CIQ for 3 months. The results of this treatment were compared with those after the 3-month AAPS phase. The primary endpoint was the change in time in range (% TIR; 70-80 mg/dL). RESULTS: Twenty-five people with diabetes (mean age 34.32 ± 11.07 years; HbA1c 6.4% ± 3%) participated in this study. CIQ was comparable with AAPS in achieving TIR (85.72% ± 7.64% vs. 84.24% ± 8.46%; P = .12). Similarly, there were no differences in percentage time above range (> 180 and > 250 mg/dL), mean sensor glucose (130.3 ± 13.9 vs. 128.3 ± 16.9 mg/dL; P = .21) or HbA1c (6.3% ± 2.1% vs. 6.4% ± 3.1%; P = .59). Percentage time below range (< 70 and < 54 mg/dL) was significantly lower using CIQ than AAPS. Even although participants were mostly satisfied with CIQ (63.6% mostly agreed, 9.1% strongly agreed), they did not plan to switch to CIQ. CONCLUSIONS: The CODIAC study is the first prospective study investigating the switch between open-source and commercially available AID systems. CIQ and AAPS were comparable in achieving TIR. However, hypoglycaemia was significantly lower with CIQ.
1st Faculty of Medicine Charles University Prague Czech Republic
3rd Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic
CGParkin Communications Inc Henderson Nevada USA
Department of Internal Medicine Masaryk Hospital Ústí nad Labem Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000148
- 003
- CZ-PrNML
- 005
- 20240228100343.0
- 007
- ta
- 008
- 240109s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/dom.15289 $2 doi
- 035 __
- $a (PubMed)37743832
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Do, Quoc Dat, $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic $d 1994- $7 xx0314623
- 245 10
- $a Comparison of Control-IQ and open-source AndroidAPS automated insulin delivery systems in adults with type 1 diabetes: The CODIAC study / $c QD. Do, A. Hásková, L. Radovnická, J. Konečná, E. Horová, CG. Parkin, G. Grunberger, M. Prázný, J. Šoupal
- 520 9_
- $a AIM: To compare open-source AndroidAPS (AAPS) and commercially available Control-IQ (CIQ) automated insulin delivery (AID) systems in a prospective, open-label, single-arm clinical trial. METHODS: Adults with type 1 diabetes who had been using AAPS by their own decision entered the first 3-month AAPS phase then were switched to CIQ for 3 months. The results of this treatment were compared with those after the 3-month AAPS phase. The primary endpoint was the change in time in range (% TIR; 70-80 mg/dL). RESULTS: Twenty-five people with diabetes (mean age 34.32 ± 11.07 years; HbA1c 6.4% ± 3%) participated in this study. CIQ was comparable with AAPS in achieving TIR (85.72% ± 7.64% vs. 84.24% ± 8.46%; P = .12). Similarly, there were no differences in percentage time above range (> 180 and > 250 mg/dL), mean sensor glucose (130.3 ± 13.9 vs. 128.3 ± 16.9 mg/dL; P = .21) or HbA1c (6.3% ± 2.1% vs. 6.4% ± 3.1%; P = .59). Percentage time below range (< 70 and < 54 mg/dL) was significantly lower using CIQ than AAPS. Even although participants were mostly satisfied with CIQ (63.6% mostly agreed, 9.1% strongly agreed), they did not plan to switch to CIQ. CONCLUSIONS: The CODIAC study is the first prospective study investigating the switch between open-source and commercially available AID systems. CIQ and AAPS were comparable in achieving TIR. However, hypoglycaemia was significantly lower with CIQ.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a diabetes mellitus 1. typu $x farmakoterapie $7 D003922
- 650 _2
- $a hypoglykemika $x terapeutické užití $7 D007004
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a glykovaný hemoglobin $7 D006442
- 650 _2
- $a inzulinové infuzní systémy $7 D007332
- 650 _2
- $a krevní glukóza $7 D001786
- 650 _2
- $a selfmonitoring glykemie $x metody $7 D015190
- 650 12
- $a inzuliny $7 D061385
- 650 _2
- $a inzulin $x terapeutické užití $7 D007328
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hásková, Aneta $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic
- 700 1_
- $a Radovnická, Lucie $u 1st Faculty of Medicine Charles University, Prague, Czech Republic $u Department of Internal Medicine, Masaryk Hospital, Ústí nad Labem, Czech Republic
- 700 1_
- $a Konečná, Judita $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic
- 700 1_
- $a Horová, Eva $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic
- 700 1_
- $a Parkin, Christopher G $u CGParkin Communications, Inc., Henderson, Nevada, USA
- 700 1_
- $a Grunberger, George $u Grunberger Diabetes Institute, Bloomfield Hills, Michigan, USA $1 https://orcid.org/0000000324310532
- 700 1_
- $a Prázný, Martin $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic
- 700 1_
- $a Šoupal, Jan $u 3rd Department of Internal Medicine, 1st Faculty of Medicine Charles University, Prague, Czech Republic $1 https://orcid.org/000000016041190X $7 xx0224300
- 773 0_
- $w MED00005425 $t Diabetes, obesity and metabolism $x 1463-1326 $g Roč. 26, č. 1 (2024), s. 78-84
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37743832 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240228100338 $b ABA008
- 999 __
- $a ok $b bmc $g 2049061 $s 1209842
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 26 $c 1 $d 78-84 $e 20230925 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
- GRA __
- $a MH CZ-DRO-VFN64165 $p Ministry of Health, Czech Republic - conceptual development of research organization, General University Hospital in Prague
- GRA __
- $p Cooperatio Program, research area "Metabolic Diseases", Charles University in Prague
- LZP __
- $a Pubmed-20240109
